Research Topics
Species | Erik PorteliusSummaryCountry: Sweden Publications
| Collaborators
|
Detail Information
Publications
A novel pathway for amyloid precursor protein processingErik Portelius
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, S 431 80 Molndal, Sweden
Neurobiol Aging 32:1090-8. 2011....- Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's diseaseErik Portelius
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, SE 431 80 Molndal, Sweden
Neurodegener Dis 6:258-62. 2009..g. Abeta1-15 and Abeta1-16), and that the levels of these shorter isoforms are elevated in media from cells that have been treated with gamma-secretase inhibitors... - Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's diseaseErik Portelius
Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
Acta Neuropathol 120:185-93. 2010..No prominent differences in Abeta isoform patterns between FAD and SAD patients were seen, underscoring the similarity in the amyloid pathology of these two disease entities... - Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluidErik Portelius
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, S 431 80 Molndal, Sweden
Exp Neurol 223:351-8. 2010.... - Identification of novel APP/Abeta isoforms in human cerebrospinal fluidErik Portelius
Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
Neurodegener Dis 6:87-94. 2009..A lot of research has focused on Abeta production and the neurotoxic 42-amino-acid form of Abeta (Abeta1-42), while less is known about the nonamyloidogenic pathway and how Abeta is degraded... - Acute effect on the A? isoform pattern in CSF in response to ?-secretase modulator and inhibitor treatment in dogsErik Portelius
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
J Alzheimers Dis 21:1005-12. 2010..The data presented suggests that the ?-secretase modulator E-2012 alters the cleavage site preference of ?-secretase. The increase in A?(1-37) may inhibit A?(1-42) oligomerization and toxicity... - Targeted proteomics in Alzheimer's disease: focus on amyloid-betaErik Portelius
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
Expert Rev Proteomics 5:225-37. 2008..From a longer perspective, establishment of the most effective combinations of different biomarkers and other diagnostic modalities may be foreseen... - Characterization of tau in cerebrospinal fluid using mass spectrometryErik Portelius
Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
J Proteome Res 7:2114-20. 2008..Nineteen tryptic fragments of tau were detected, of which 16 are found in all tau isoforms while 3 represented unique tau isoforms. These results pave the way for clinical CSF studies on the tauopathies... - Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometryErik Portelius
Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
J Proteome Res 6:4433-9. 2007..Finally, we report the finding of two novel Abeta peptides (Abeta2-17 and Abeta3-17)... - Novel a? isoforms in Alzheimer's disease - their role in diagnosis and treatmentErik Portelius
Clinical Neurochemistry Laboratory Institute of Neuroscience and Physiology Dept of Psychiatry and Neurochemistry The Sahlgrenska Academy at the University of Gothenburg Sahlgrenska University Hospital, Mölndal SE 431 80 Mölndal, Sweden
Curr Pharm Des 17:2594-602. 2011..Here, we review the many aspects of A? and its isoforms with special focus on their potential role as diagnostic and theragnostic markers... - An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluidErik Portelius
Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
Neurosci Lett 409:215-9. 2006..Here, we provide direct evidence that an Abeta fragment signature consisting of Abeta1-16, Abeta1-33, Abeta1-39, and Abeta1-42 in CSF distinguishes sporadic AD patients from non-demented controls with an overall accuracy of 86%... - Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometryErik Portelius
Institute of Clinical Neuroscience, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180 Mölndal, Sweden
J Proteome Res 5:1010-6. 2006..Finally, the Abeta fragment signatures may prove useful as a diagnostic test for AD... - A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer diseaseErik Portelius
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, SE 431 80, Sweden
Alzheimers Res Ther 2:7. 2010..These Abeta isoforms may be novel sensitive biomarkers to monitor the biochemical effect in clinical trials. TRIAL REGISTRATION : Clinical Trials.gov NCT00244322... - Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseasesAnn Westman-Brinkmalm
Institute of Neuroscience and Physiology, Department of Psychiatry and Neuochemistry, The Sahlgrenska Academy at Goteborg University, Sweden
Front Biosci 14:1793-806. 2009..In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations... - An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid ? and amyloid precursor protein in human and cat cerebrospinal fluidGunnar Brinkmalm
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
J Mass Spectrom 47:591-603. 2012..We here describe a detailed characterization of endogenous APP/A? peptide species in CSF by using an online top-down MS-based method. Copyright © 2012 John Wiley & Sons, Ltd... - Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluidAdnan Halim
Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, SE 413 45 Gothenburg, Sweden
Proc Natl Acad Sci U S A 108:11848-53. 2011..APP/A? sialylated O-glycans, including that of a Tyr residue, the first in a mammalian protein, may modulate APP processing, inhibiting the amyloidogenic pathway associated with AD... - Synaptic retrogenesis and amyloid-beta in Alzheimer's diseasePontus Wasling
Department of Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
J Alzheimers Dis 16:1-14. 2009..Here, we review the literature on the possible physiological roles of Abeta and its precursor protein AbetaPP during development with special focus on electrophysiological findings... - Evaluation of the performance of novel a? isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patientErik Portelius
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
Neurodegener Dis 10:138-40. 2012.... - BACE1 inhibition induces a specific cerebrospinal fluid ?-amyloid pattern that identifies drug effects in the central nervous systemNiklas Mattsson
Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
PLoS ONE 7:e31084. 2012..The described CSF A? pattern may be used as a pharmacodynamic fingerprint to detect biochemical effects of BACE1-therapies in clinical trials, which might accelerate development of novel therapies... - The amyloid-? isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's diseaseErik Portelius
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
Mol Med Report 5:1111-5. 2012.... - Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantitation of proteins in a SILAC experimentAnnika Thorsell
Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Rapid Commun Mass Spectrom 21:771-8. 2007..Furthermore, the fractionation enhanced the number of identified proteins and improved their quantitation... - Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesisAngela D Williams
Graduate School of Medicine, R221, University of Tennessee, 1924 Alcoa Highway, Knoxville, TN 37920, USA
J Mol Biol 335:833-42. 2004....